You may be right, dog. The MOS in the front line NSCLC trial may not move the share price immediately. In view of the twice postponed trial results, perhaps the data will move the street. Can't say till we actually see the data.
However, I think you are also right that the numbers will probably be good enough to motivate BPs to pull the partnership trigger. They could be solid enough to move the FDA without moving the street. As long as the BPs and the FDA are moved, we will get our price in the near future. That would be good enough for me.
Paul
News 
Market Data 
Discover 
